How Long Do Reglan Tardive Dyskinesia Symptoms Last in Georgia?

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

What is the statute of limitations for Reglan tardive dyskinesia claims in Georgia

In Georgia, the statute of limitations for personal injury claims, including those from Reglan-induced tardive dyskinesia, is generally two years from the date of injury or discovery. However, specific circumstances may affect this timeline. Consult a qualified attorney for guidance on your case.

From General Health Information to Targeted Risk Assessment

If you or a loved one developed tardive dyskinesia after taking Reglan, you may be wondering how long the symptoms will last. Decades of pharmacovigilance and clinical research have established that these involuntary movements can persist long after stopping the drug, sometimes permanently. This page reviews the published evidence on symptom duration and what it means for Georgia residents.

Understanding Reglan and Its Approved Uses

Reglan (metoclopramide) is a prescription medication approved for short-term treatment of symptomatic gastroesophageal reflux in adults who have not responded to conventional therapy, and for relief of symptoms in adults with acute and recurrent diabetic gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The drug carries a boxed warning stating that metoclopramide, including Reglan, can cause tardive dyskinesia (TD), a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). TD is characterized by involuntary, repetitive movements of the face, tongue, trunk, and extremities, and may be disfiguring (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with longer duration of treatment and higher total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD, and the drug should be used for the shortest duration necessary, with periodic reassessment of the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If signs or symptoms of TD develop, Reglan should be immediately discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic gastroesophageal reflux, the maximum approved duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). In patients with diabetic gastroparesis, total treatment duration should also be limited to 12 weeks; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan tablets are not recommended for use in pediatric patients due to the risk of developing TD and other extrapyramidal symptoms, as well as the risk of methemoglobinemia in neonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Mechanism and Clinical Presentation of Tardive Dyskinesia

The mechanistic pathway linking Reglan to TD involves metoclopramide's dopamine D2 receptor antagonism in the basal ganglia, which can lead to supersensitivity of dopamine receptors and subsequent involuntary movements. This effect is dose-dependent and cumulative, with prolonged exposure increasing the likelihood of irreversible neurological damage. The clinical presentation of TD typically includes orofacial movements such as lip smacking, tongue protrusion, and grimacing, as well as choreiform movements of the limbs and trunk. Diagnosis is based on clinical history and physical examination, often using standardized rating scales like the Abnormal Involuntary Movement Scale (AIMS). Early detection is critical, as TD can become permanent even after drug discontinuation. The timeline between Reglan exposure and documented harm is variable. TD may appear during treatment, after dose reduction, or after discontinuation. Some patients develop symptoms within weeks, while others may not show signs until after years of use. Because Reglan can suppress or partially suppress the signs of TD, the diagnosis may be delayed (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Once TD is diagnosed, the condition is often irreversible, and treatment options are limited to managing symptoms with medications such as valbenazine or deutetrabenazine, which are FDA-approved for TD but may not fully resolve movements.

Statute of Limitations for Reglan Claims in Georgia

In Georgia, the statute of limitations for filing a personal injury lawsuit related to Reglan-induced TD is generally two years from the date the injury was discovered or reasonably should have been discovered. This discovery rule is important because TD may develop months or years after Reglan exposure, and symptoms may be subtle initially. Patients who took Reglan for longer than 12 weeks, or who were not warned about the risk of TD, may have a viable claim. Settlement considerations for affected patients include the severity of TD symptoms, the duration and dosage of Reglan use, the adequacy of warnings provided by the prescribing physician or manufacturer, and the impact on quality of life. The FDA boxed warning explicitly states that Reglan can cause TD and that risk increases with treatment duration and cumulative dose (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). However, many patients report that they were not adequately informed of this risk before starting treatment. For patients in Georgia considering legal action, it is essential to document the exact dates of Reglan use, the prescribing physician, and any warnings received. Medical records should include evidence of TD diagnosis, such as AIMS scores and neurological evaluations. The statute of limitations clock typically starts when the patient knew or should have known that TD was caused by Reglan. Consulting with an attorney experienced in pharmaceutical litigation is recommended to assess individual circumstances and ensure timely filing.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan-induced tardive dyskinesia claims in Georgia?

In Georgia, the statute of limitations for personal injury claims related to Reglan-induced tardive dyskinesia is generally two years from the date the injury was discovered or reasonably should have been discovered. This discovery rule is important because TD symptoms may appear months or years after Reglan exposure.

Can I still file a claim if my tardive dyskinesia was diagnosed years after taking Reglan?

Yes, because the statute of limitations in Georgia is based on the discovery rule. The clock starts when you knew or should have known that Reglan caused your TD. It is crucial to document your Reglan use and diagnosis and consult an attorney promptly.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.